KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Non Operating Income (2018 - 2025)

Inovio Pharmaceuticals' Non Operating Income history spans 10 years, with the latest figure at -$1.9 million for Q3 2025.

  • For Q3 2025, Non Operating Income fell 234.28% year-over-year to -$1.9 million; the TTM value through Sep 2025 reached -$4.6 million, down 115.15%, while the annual FY2024 figure was -$3.2 million, 32.85% up from the prior year.
  • Non Operating Income for Q3 2025 was -$1.9 million at Inovio Pharmaceuticals, down from -$703183.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $185281.0 in Q2 2021 and bottomed at -$2.8 million in Q4 2022.
  • The 5-year median for Non Operating Income is -$579819.0 (2024), against an average of -$738706.4.
  • The largest annual shift saw Non Operating Income skyrocketed 1799.44% in 2021 before it tumbled 46746.03% in 2023.
  • A 5-year view of Non Operating Income shows it stood at $177598.0 in 2021, then tumbled by 1656.49% to -$2.8 million in 2022, then surged by 68.86% to -$860908.0 in 2023, then crashed by 121.77% to -$1.9 million in 2024, then fell by 1.52% to -$1.9 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Non Operating Income are -$1.9 million (Q3 2025), -$703183.0 (Q2 2025), and -$482.0 (Q1 2025).